The EMA's financial juggling act
This article was originally published in SRA
Executive Summary
The European Medicines Agency is in the spotlight this week over the speed with which its former executive director, Thomas Lönngren, took up a post in the private sector. Public health groups have written to the European Commission claiming that the EMA did not follow EU procedures intended to prevent undue influence in the regulatory process, and should have imposed a "cooling off" period for Mr Lönngren to safeguard against potential conflicts of interest.